ClinicalTrials.gg
TerminatedNCT00343980Updated Mar 1, 2017

Safety and Efficacy of Inhaled Pre-prandial Human Insulin in Type 2 Diabetes

A Phase 3 interventional study of rosiglitazone and inhaled human insulin in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Terminated at 26 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-03-01.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

How we know

Why this study was terminated
See termination reason in detailed description

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
363
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2 — none open to participants now, 1 under way, none of them phase 3. Insulin, Regular, Human · Diabetes Mellitus, Type 2.

Enrollment
13th of 49
363 · median 129
Started
2006
with 9 others
Phase 3
25 of 49
none open now
Registered
9th of 49
by date
Lead sponsor
10 of 49
Novo Nordisk A/S

Among the 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2, this one is the 13th largest by enrollment, is one of 10 that started in 2006, is one of 25 in phase 3, and was the 9th registered.

Diabetes Mellitus, Type 2

10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

About Insulin, Regular, Human

Insulin, Regular, Human: first FDA approval 1982 (HUMULIN R PEN), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2 as a file.
02

Study summary

This trial is conducted in Asia, Europe and Oceania. The aim of this research study is to compare the efficacy of adding inhaled preprandial insulin to glimepiride compared to adding rosiglitazone to glimepiride for the treatment of type 2 diabetes and to verify its safety (hypoglycaemia, pulmonary function, body weight, insulin antibodies and side effects)

Read the detailed description

The decision to discontinue the development of AERx® is not due to any safety concerns. An analysis concluded that fast-acting inhaled insulin in the form it is known today, is unlikely to offer significant clinical or convenience benefits over injections of modern insulin with pen devices.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 2

Browse trials for

04

In context

Diabetes Mellitus, Type 2 Reclassified

10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

This study's enrollment of 363 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,411 studies on the registry; 108 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 2 diabetes
  • Treated with OAD(s) for more than or equal to 2 months
  • (BMI) less than or equal to 40.0 kg/m2
  • greater than or equal to 8.0 % and less than or equal to 11.0 % for subjects in OAD monotherapy
  • HbA1c greater than or equal to 7.5 % and less than or equal to 10.0 % for subjects on OAD combination therapy

Exclusion criteria

Exclusion Criteria:

  • Recurrent major hypoglycaemia
  • Current smoking or smoking within the last 6 months
  • Impaired hepatic or renal function
  • Cardiac problems
  • Uncontrolled hypertension
  • Proliferative retinopathy or maculopathy
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
363 participants (actual)

Study arms

  • Experimental
    A

    Drug: inhaled human insulin · Drug: glimepiride

  • Active comparator
    B

    Drug: rosiglitazone · Drug: glimepiride

Interventions

07

What researchers measure

Primary outcomes

  1. Treatment difference in HbA1c

    Time frame: After 26 weeks

Secondary outcomes

  1. Adverse events

    Time frame: For the duration of the trial

  2. Body weight

    Time frame: during treatment

  3. Lung function

    Time frame: after 26 weeks of treatment

  4. Blood glucose

    Time frame: after 26 weeks of treatment

  5. Hypoglycaemia

    Time frame: from 12-26 weeks of treatment

08

Study locations

26 sites
  • Novo Nordisk Investigational Site
    St Leonards, New South Wales 2065, Australia
  • Novo Nordisk Investigational Site
    Wollongong, New South Wales 2500, Australia
  • Novo Nordisk Investigational Site
    Garran, 2605, Australia
  • Novo Nordisk Investigational Site
    Kingswood, 2747, Australia
  • Novo Nordisk Investigational Site
    Osijek, 31 000, Croatia
  • Novo Nordisk Investigational Site
    Zagreb, 10 000, Croatia
  • Novo Nordisk Investigational Site
    Chennai, Tamil Nadu 600086, India
  • Novo Nordisk Investigational Site
    Vellore, Tamil Nadu 632004, India
  • Novo Nordisk Investigational Site
    Bangalore, 560010, India
  • Novo Nordisk Investigational Site
    Chennai, 600020, India
  • Novo Nordisk Investigational Site
    Coimbatore, 641002, India
  • Novo Nordisk Investigational Site
    Skopje, 1000, Macedonia, The Former Yugoslav Republic of
  • Novo Nordisk Investigational Site
    Cebu City, 6000, Philippines
  • Novo Nordisk Investigational Site
    Makati City, 1200, Philippines
  • Novo Nordisk Investigational Site
    Manila, 1000, Philippines
  • Novo Nordisk Investigational Site
    Moscow, 119034, Russian Federation
  • Novo Nordisk Investigational Site
    Moscow, 121356, Russian Federation
  • Novo Nordisk Investigational Site
    Moscow, 127486, Russian Federation
  • Novo Nordisk Investigational Site
    Moscow, 127644, Russian Federation
  • Novo Nordisk Investigational Site
    Saint-Petersburg, 194354, Russian Federation
  • Novo Nordisk Investigational Site
    Saint-Petersburg, 198013, Russian Federation
  • Novo Nordisk Investigational Site
    Bornova-IZMIR, 35100, Turkey
  • Novo Nordisk Investigational Site
    Bursa, 16059, Turkey
  • Novo Nordisk Investigational Site
    Istanbul, 34098, Turkey
  • Novo Nordisk Investigational Site
    Istanbul, 34390, Turkey
  • Novo Nordisk Investigational Site
    Istanbul, 34718, Turkey
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2006 to primary completion in Mar 2008, 17 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2006
First posted
Jun 23, 2006
StartActual
Oct 10, 2006
Primary completionActual
Mar 10, 2008
CompletionActual
Mar 10, 2008
Last update
Mar 1, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 1, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00343980
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jun 23, 2006
Start date
Oct 10, 2006
Primary completion
Mar 10, 2008
Completion
Mar 10, 2008
Last update
Mar 1, 2017

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin, Regular, Human

Start the discussion